Close Menu

NEW YORK – The COVID-19 pandemic has thus far presented many life science research tool providers and fledgling diagnostic firms with an immediate opportunity to generate meaningful revenues from diagnostic testing in 2020.

For some firms, this opportunity may be short-lived. For others, it will perhaps serve as a launching pad for sustainable, long-term growth driven by diagnostic testing.

Fluidigm President and CEO Chris Linthwaite this week made it clear that he sees his company, long a pure-play omics research firm, in the latter category.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.